Status:

COMPLETED

Individualized Neuromodulation for the Core Clinical Features of Drug Addiction

Lead Sponsor:

Shanghai Mental Health Center

Conditions:

Amphetamine Use Disorders

Eligibility:

All Genders

18-45 years

Phase:

NA

Brief Summary

Using specific EEG biomarkers in methamphetamine-dependent individuals, this study systematically probes closed-loop tACS based on brain states, assessing dosage, neurologic and behavioral effects, wh...

Detailed Description

The current study delineates a robust correlation between prefrontal cortex EEG signals and the psychological craving associated with methamphetamine usage. Dependents exhibit heightened β oscillation...

Eligibility Criteria

Inclusion

  • Individuals aged between 18 and 45 years, irrespective of gender, having completed a minimum of 9 years of education and capable of effectively cooperating in questionnaire evaluations.
  • Meet the diagnostic criteria set forth by the DSM-V concerning the severity of amphetamine-type substance addiction.
  • A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week.
  • Consent to actively cooperate in the completion of subsequent follow-up assessments.

Exclusion

  • Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70.
  • A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria.
  • Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years.
  • Severe organic diseases that might compromise study participation.
  • Contraindications to tACS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.

Key Trial Info

Start Date :

September 25 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 25 2024

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT06165198

Start Date

September 25 2023

End Date

September 25 2024

Last Update

November 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China, 200000